Poor
Major Misalignment
Patient Risk:
High
Summary
Only a small subset of claims are supported by the provided FDA label excerpts (notably indications and one specific dose-limit interaction). Many other claims introduce specific incidence/percent/fold-change figures, mechanistic consequences, and monitoring/counseling details that are not supported by the supplied label text excerpts, creating substantial label-mismatch risk.
Category Scores
Accurate Statements
Simvastatin is used to lower cholesterol.
1 INDICATIONS AND USAGE (adjunct to diet to reduce LDL-C; reduce risk of mortality by reducing risk of coronary heart disease death, etc.)
Risk of muscle damage with simvastatin is increased by older age (≥65 years).
8.5 Geriatric Use (advanced age is a risk factor; increased risk of myopathy including rhabdomyolysis in patients ≥65; monitor increased risk)
Avoiding simvastatin doses over 20 mg with amlodipine or ranolazine is recommended.
2.5 Dosage Modifications Due to Drug Interactions (Patients taking Amiodarone, Amlodipine, or Ranolazine: Do not exceed ZOCOR 20 mg once daily)
Unsupported Statements
Simvastatin commonly causes muscle pain (myalgia), headache, nausea, and digestive issues such as constipation or diarrhea.
The provided label excerpts do not include these adverse-event frequency statements.
The rate of common side effects of simvastatin is 1-10% of users.
No such frequency range is supported by the supplied excerpts.
Common side effects of simvastatin often resolve after stopping the drug.
No such resolution statement is supported by the supplied excerpts.
Myopathy occurs in about 0.1-0.5% of simvastatin-treated patients.
No incidence range is supported by the supplied excerpts.
Rhabdomyolysis from simvastatin occurs in rare cases at about 1 in 10,000.
No such absolute incidence is supported by the supplied excerpts.
Rhabdomyolysis from simvastatin can lead to kidney failure due to muscle breakdown releasing myoglobin.
The supplied excerpts only reference myopathy/rhabdomyolysis generally; the kidney-failure/myoglobin mechanism is not present in provided text.
Risk of muscle damage with simvastatin rises with higher doses above 20 mg/day.
No dose-threshold relationship for muscle risk is supported by the supplied excerpts.
Risk of muscle damage with simvastatin is increased by female sex.
No sex-based muscle risk statement is supported by the supplied excerpts.
Risk of muscle damage with simvastatin is increased by low body weight.
No low body weight risk statement is supported by the supplied excerpts.
Risk of muscle damage with simvastatin is increased by kidney impairment.
The provided excerpts discuss renal starting dose but do not support a muscle-risk increase due to renal impairment.
Risk of muscle damage with simvastatin is increased by liver impairment.
Provided excerpts include liver contraindication (acute liver failure/decompensated cirrhosis) but do not support increased myopathy risk from liver impairment.
Simvastatin can raise liver enzymes (ALT/AST) in 0.5-2% of users.
No such ALT/AST incidence range is supported by the supplied excerpts.
Liver enzyme elevation with simvastatin can signal potential liver damage.
While hepatic dysfunction is referenced, the supplied excerpts do not support this specific interpretive statement.
Severe hepatitis or liver failure with simvastatin is rare (under 0.1%).
No such rate is supported by the supplied excerpts.
Routine monitoring is advised for liver enzymes in simvastatin users, especially in the first year.
The supplied excerpts do not specify routine liver-enzyme monitoring timing/frequency.
Simvastatin increases new-onset diabetes risk by 9-12% in predisposed patients.
The supplied excerpts do not provide any quantitative diabetes incidence/risk increase.
The increased diabetes risk with simvastatin is dose-dependent.
No dose-dependence statement is supported by the supplied excerpts.
Predisposed patients for simvastatin-associated diabetes risk include those with obesity or prediabetes.
No such patient-risk characterization is supported by the supplied excerpts.
Mild cognitive issues such as memory loss or confusion occur in under 1% of simvastatin users, per FDA reports.
No cognitive adverse-event incidence or 'FDA reports' support is present in the supplied excerpts.
Peripheral neuropathy is also rare with simvastatin.
No peripheral neuropathy statement is supported by the supplied excerpts.
Strong CYP3A4 inhibitors such as itraconazole, erythromycin, and verapamil increase simvastatin levels by 5-10 fold.
While CYP3A4 inhibitor interactions are referenced and Table 4 includes examples, the supplied excerpts do not support a universal '5-10 fold' figure across the named drugs.
Increased simvastatin levels due to strong CYP3A4 inhibitors increase myopathy risk to 1-5%.
No such myopathy-risk percentage is supported by the supplied excerpts.
SLCO1B1 gene variants raise simvastatin myopathy odds by 4-fold in certain populations.
No pharmacogenomic statement is supported by the supplied excerpts.
Hypothyroidism increases muscle risk with simvastatin.
No hypothyroidism-to-muscle-risk statement is supported by the supplied excerpts.
Heavy alcohol use increases muscle risk with simvastatin.
No alcohol-to-muscle-risk statement is supported by the supplied excerpts.
Intense exercise increases muscle risk with simvastatin.
No exercise-to-muscle-risk statement is supported by the supplied excerpts.
Simvastatin is contraindicated in active liver disease.
The supplied excerpts only specify contraindication for acute liver failure or decompensated cirrhosis, not general 'active liver disease.'
Simvastatin is contraindicated in pregnancy (category X) due to fetal harm risk.
The pregnancy excerpt describes fetal harm mechanism and discontinuation when pregnancy is recognized, but provided excerpts do not state 'contraindicated' or 'category X.'
Simvastatin is contraindicated in breastfeeding.
The supplied excerpts state breastfeeding is not recommended, but do not label it as a contraindication.
Simvastatin is contraindicated in unexplained persistent liver enzyme elevations.
No such contraindication is supported by the supplied excerpts.
Use of simvastatin requires caution in Asians due to higher plasma levels at the 40 mg dose.
No Asian-specific caution statement is supported by the supplied excerpts.
There is no strong evidence of increased cancer risk after 5+ years of simvastatin use.
No cancer-risk/evidence statements are supported by the supplied excerpts.
Hemorrhagic stroke risk may rise slightly with simvastatin, with an absolute increase of 0.2-0.5%.
No hemorrhagic stroke risk/absolute increase is supported by the supplied excerpts.
Guidelines recommend baseline and periodic liver/muscle tests for simvastatin.
No such guidelines/monitoring schedule statements are supported by the supplied excerpts.
Guidelines recommend CK levels if symptoms suggest muscle injury in simvastatin users.
No CK testing recommendation is supported by the supplied excerpts.
Contradictions
Important Omissions
The label excerpted here specifies contraindications for concomitant use of strong CYP3A4 inhibitors, cyclosporine/danazol/gemfibrozil, and acute liver failure or decompensated cirrhosis, plus hypersensitivity. The extracted claims did not reflect these contraindication details (e.g., strong CYP3A4 inhibitor concomitant use).
Importance:
Moderate
The label excerpted here states lactation: breastfeeding is not recommended during treatment. The extracted claims assert 'contraindicated' breastfeeding, which implies omission of the label's actual phrasing/position.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Many statements include quantitative incidence/risk estimates, mechanistic consequences, and categorical contraindication assertions that are not supported by the provided label excerpts, potentially leading to label-inconsistent risk perception, monitoring expectations, or prescribing decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Major Misalignment
Primary Issue
Large volume of unsupported quantitative safety and contraindication claims not present in the provided label excerpts (myopathy/rhabdomyolysis incidence and consequences; liver enzyme rates; diabetes magnitude/dose-dependence; cognitive/neuropathy; stroke absolute increase; and multiple contraindications asserted with category/label-status language).
Suggested Improvement
Restrict claims to text explicitly supported by the provided label excerpts (indications; geriatric myopathy risk; specific dose limits with amlodipine/rakinolazine; pregnancy counseling language about discontinuation due to fetal harm; contraindications as explicitly listed for specific agents/conditions). Remove or rephrase unsupported quantitative risk estimates and any contraindication/category assertions not present in the supplied label text.